<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS136379</article-id>
<article-id pub-id-type="doi">10.1101/2021.10.06.463309</article-id>
<article-id pub-id-type="archive">PPR405151</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Measuring host immune response status by simultaneous quantitative measurement of activity of signal transduction pathways that coordinate functional activity of immune cells from innate and adaptive immune system</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bouwman</surname>
<given-names>Wilbert</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Verhaegh</surname>
<given-names>Wim</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Doorn</surname>
<given-names>Arie</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>van de Stolpe</surname>
<given-names>Anja</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Philips Research, Eindhoven, The Netherlands</aff>
<aff id="A2">
<label>2</label>Philips Molecular Pathway Dx (<ext-link ext-link-type="uri" xlink:href="http://www.philips.com/oncosignal">www.philips.com/oncosignal</ext-link>), Eindhoven, The Netherlands</aff>
<author-notes>
<corresp id="CR1">Philips Molecular Pathway Dx (<ext-link ext-link-type="uri" xlink:href="http://www.philips.com/oncosignal">www.philips.com/oncosignal</ext-link>), Eindhoven, The Netherlands, <email>Anja.van.de.stolpe@philips.com</email>, +31 6 12784841</corresp>
<fn id="FN1" fn-type="con">
<p id="P1">
<bold>Author contributions:</bold>
</p>
<p id="P2">Wilbert Bouwman: Data analysis, figures, writing</p>
<p id="P3">Wim Verhaegh: Pathway model development, data analysis, figures</p>
<p id="P4">Arie van Doorn: Data analysis</p>
<p id="P5">Anja van de Stolpe: concept, data analysis, writing</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>09</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>07</day>
<month>10</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref>
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<p id="P6">For many diseases, including cancer, viral infections such as COVID-19, bacterial infections, and auto-immune diseases, the immune response is a major determinant of progression, response to therapy, and clinical outcome. Innate and adaptive immune response are controlled by coordinated activity of multiple immune cell types. The functional activity state of immune cells is determined by cellular signal transduction pathways (STPs). A novel mRNA-based signaling pathway assay platform has been developed to quantitatively measure relevant STP activities in all types of immune cells and mixed immune cell samples for experimental and diagnostic purposes. We generated a STP activity profile, termed Immune-Pathway Activity Profile (I-PAP), for a variety of immune cell types in resting and activated state, and provide a first example for use in patient samples.</p>
<sec id="S1">
<title>Methods</title>
<p id="P7">The technology to measure STP activity has been described for androgen and estrogen receptor, PI3K, MAPK, TGFβ, Notch, NFκB, JAK-STAT1/2, and JAK-STAT3 pathways. STP activity was measured on Affymetrix expression microarray data from preclinical studies containing public data from different types of immune cells, resting/naïve or immune-activated <italic>in vitro</italic>, to establish I-PAPs. Subsequently data from a clinical study on rheumatoid arthritis were analyzed.</p>
</sec>
<sec id="S2">
<title>Results</title>
<p id="P8">I-PAPs of naïve/resting and immune-activated CD4+ and CD8+ T cells, T helper cells, B cells, NK cells, monocytes, macrophages, and dendritic cells were established and in agreement with known experimental immunobiology. In whole blood samples of rheumatoid arthritis patients TGFβ pathway activity was increased; JAK-STAT3 pathway activity was selectively increased in female patients. In naïve CD4+ Tregs TGFβ pathway activity was increased, while in memory T effector cells JAK-STAT3 pathway activity tended to increase, suggesting that these immune cell types contributed to whole blood analysis results.</p>
</sec>
<sec id="S3">
<title>Conclusion</title>
<p id="P9">STP assay technology (currently being converted to qPCR-based assays) makes it possible to directly measure functional activity of cells of the innate and adaptive immune response enabling quantitative assessment of the immune response of an individual patient. Envisioned utility lies in (1) prediction and monitoring of response to immunomodulatory treatments for a variety of immune-mediated diseases, including RA; (2) uncovering novel treatment targets; (3) improvement and standardization of <italic>in vitro</italic> immunology research and drug development.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="S4" sec-type="intro">
<title>Introduction</title>
<p id="P10">The immune response is determined by the coordinated activity of a number of immune cell types belonging to the innate or adaptive immune system (<xref ref-type="bibr" rid="R13">Davis, n.d.</xref>) (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Immune cells communicate through a variety of ligands that bind specifically to receptors on the cell membrane or inside the cell (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Upon ligand binding, receptors specifically activate signal transduction pathways (STPs), which through intracellular crosstalk may activate other STPs, resulting in highly controlled changes in cell function (<xref ref-type="bibr" rid="R10">Cantley et al., 2014</xref>). Every immune cell type has its own set of membrane receptors and signal transduction pathways (STPs) determining to which signals the cell will respond. Growth hormones, cytokines, interferons, estrogens and androgens, are signals that act in concert to control activity of STPs such as PI3K-FOXO, MAPK, JAK-STAT1/2 and JAK-STAT 3, NFκB, TGFβ, Notch, estrogen (ER) and androgen (AR) receptor pathways, to regulate functions such as immune cell maturation and activation (<xref ref-type="bibr" rid="R24">Han et al., 2012</xref>),(<xref ref-type="bibr" rid="R42">Platanias, 2005</xref>),(<xref ref-type="bibr" rid="R39">Oh and Ghosh, 2013</xref>),(<xref ref-type="bibr" rid="R31">Li et al., 2007</xref>),(<xref ref-type="bibr" rid="R22">Goodman et al., 2011</xref>),(<xref ref-type="bibr" rid="R41">Perchet et al., 2018</xref>),(<xref ref-type="bibr" rid="R14">Deftos and Bevan, 2000</xref>),(<xref ref-type="bibr" rid="R32">Liu et al., 2007</xref>),(<xref ref-type="bibr" rid="R30">Lai et al., 2012</xref>),(<xref ref-type="bibr" rid="R29">Kovats, 2015</xref>). Ligand activated STP activity can be regulated in a ligand-dependent manner or through intracellular crosstalk between STPs.</p>
<p id="P11">Using a previously reported novel assay technology, we measured activity of immunologically relevant STPs in different types of immune cells, in naïve or resting and immune-activated state. Based on the results, we determined an Immune-signal transduction Pathway Activity Profile (I-PAP) for each cell type, in the two different functional states. To explore clinical value of the assay technology, STP activity was measured in blood samples of patients with rheumatoid arthritis (RA).</p>
</sec>
<sec id="S5" sec-type="methods">
<title>Methods</title>
<sec id="S6">
<title>Measurement of activity of signal transduction pathways on Affymetrix microarray data from cell samples</title>
<p id="P12">Development and validation of Affymetrix-based assays for measuring activity of the estrogen (ER) and androgen receptor (AR), PI3K-FOXO, MAPK, NFκB, TGFβ, Notch, JAK-STAT1/2, and JAK-STAT3 pathways has been described before, and can in principle be used to analyze pathway activity on any cell type (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>),(<xref ref-type="bibr" rid="R54">Verhaegh et al., 2014</xref>),(<xref ref-type="bibr" rid="R48">Stolpe et al., 2019</xref>),(<xref ref-type="bibr" rid="R9">Canté-Barrett et al., 2020</xref>),(<xref ref-type="bibr" rid="R56">Wesseling-Rozendaal et al., 2021</xref>),(<xref ref-type="bibr" rid="R53">van Ooijen et al., 2018</xref>) including blood cells (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>),(<xref ref-type="bibr" rid="R57">Wesseling-Rozendaal et al., 2020</xref>),(<xref ref-type="bibr" rid="R52">van de Stolpe et al., 2021</xref>),(<xref ref-type="bibr" rid="R8">Bouwman et al., 2021</xref>). For the current study, quantitative pathway activity scores (PAS) were measured on Affymetrix expression microarray data.</p>
<p id="P13">Publicly available Affymetrix expression microarray data were derived from the GEO database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gds/">https://www.ncbi.nlm.nih.gov/gds/</ext-link>) (<xref ref-type="bibr" rid="R21">“GEO database: https://www.ncbi.nlm.nih.gov/gds/,” n.d.</xref>). For each signaling pathway, PAS were presented on a log2 odds scale. The log2 odds score for pathway activity is derived from the probability score for activity of the pathway-associated transcription factor calculated by the computational model, as described (<xref ref-type="bibr" rid="R54">Verhaegh et al., 2014</xref>),(<xref ref-type="bibr" rid="R53">van Ooijen et al., 2018</xref>),(<xref ref-type="bibr" rid="R48">Stolpe et al., 2019</xref>). Of note, PI3K pathway activity is inversely related to the measured activity of transcription factor FOXO (FOXO PAS) (<xref ref-type="bibr" rid="R53">van Ooijen et al., 2018</xref>). For this reason, FOXO activity score is presented in the figures, while interpretation regarding PI3K pathway activity can be found in legends and text.</p>
<sec id="S7">
<title>Determination of an Immune-signal transduction Pathway Activity Profile (I-PAP)</title>
<p id="P14">Combining the PAS for the nine measured STPs we tried to derive characteristic I-PAPs for the analyzed immune cell types and their functional states. Since we did not (yet) want to use absolute PAS for this purpose, relative differences (significant) in PAS between different immune cell types, or between resting/naïve and activated functional state of a specific immune cell type, were used. When an STP was significantly more active in a cell type (e.g. monocytes) compared to another cell type or types, the STP was included in the I-PAP of that cell type (monocytes). Similarly, when an STP was more active in one functional state (e.g. monocyte, resting state) compared to the other (monocyte activated) the STP was include in the I-PAP of that functional state (monocyte, resting state).</p>
<p id="P15">For CD8+ and NK cells, resting/naïve compared to activated functional state, sample numbers were too low (&lt;3) to perform statistics. For these cases we decided to determine tentative I-PAPs by including STPs that had no overlapping PAS scores between the compared functional states. If two analyzed datasets were available for the same cell type (noted by an asterisk in <xref ref-type="table" rid="T1">Table 1</xref>-<xref ref-type="table" rid="T4">4</xref>), allowing comparison of results between independent studies, analysis results from one set are in the Supplement.</p>
</sec>
<sec id="S8">
<title>Microarray Data Quality Control</title>
<p id="P16">Quality control (QC) was performed on Affymetrix data of each individual sample, as described before (<xref ref-type="bibr" rid="R48">Stolpe et al., 2019</xref>). In summary, QC parameters include: the average value of all probe intensities, presence of negative, or extremely high (&gt; 16-bit) intensity values, poly-A RNA (sample preparation spike-ins), and labelled cRNA (hybridization spike ins) controls, <italic>GAPDH</italic>, and <italic>ACTB</italic> 3'/5' ratio, centre of intensity and values of positive and negative border controls determined by affyQCReport package in R, and an RNA degradation value determined by the AffyRNAdeg function from the Affymetrix package in R (<xref ref-type="bibr" rid="R40">Parman C, Halling C, Gentleman R., n.d.</xref>), (<xref ref-type="bibr" rid="R20">Gautier et al., 2004</xref>). Sample data that failed QC were removed prior to data analysis, except for the neutrophil datasets that failed on reference genes QC parameter, and the B cell dataset that failed on CMoff QC-parameter.</p>
</sec>
<sec id="S9">
<title>Affymetrix microarray datasets from preclinical and clinical studies</title>
<p id="P17">The following AffymetrixU133Plus2.0 microarray expression datasets (publicly available) from preclinical and clinical studies, deposited in the GEO database, were analyzed (<xref ref-type="bibr" rid="R21">“GEO database: https://www.ncbi.nlm.nih.gov/gds/,” n.d.</xref>).</p>
<p id="P18">For each sample the type of immune cell (e.g. NK cell) and functional activity (e.g. resting/naïve or activated) was defined by the authors of the corresponding paper or present in the annotation provided by GEO. <list list-type="order" id="L1">
<list-item>
<p id="P19">GSE72642. Immune blood cell types (CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ natural killer cells, CD14+ monocytes and PMN (polymorphonuclear cells) isolated from peripheral blood from healthy volunteers (<xref ref-type="bibr" rid="R16">Du et al., 2006</xref>).</p>
</list-item>
<list-item>
<p id="P20">GSE15743. Natural Killer (NK) cells isolated from peripheral blood of healthy individuals, resting and activated by incubation for six hours with two concentrations (1 and 100 ng/ml) interferon alpha (IFNα), <italic>in vitro</italic> (<xref ref-type="bibr" rid="R47">Stegmann et al., 2010</xref>).</p>
</list-item>
<list-item>
<p id="P21">GSE28490. Neutrophils, Eosinophils, Monocytes, CD4+ T cells, CD8+ T cells, NK cells, B cells, pDCs and mDCs isolated from healthy human blood. Cell types were isolated from 5 pools of 5 healthy donors each, with the exception for monocytes, where 10 pools were used. <italic>(</italic>
<xref ref-type="bibr" rid="R1">Allantaz et al., 2012</xref>
<italic>)</italic>
</p>
</list-item>
<list-item>
<p id="P22">GSE22103. Neutrophils, isolated from peripheral blood of healthy individuals, resting and activated with Escherichia coli lipopolysaccharide (LPS) or granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (INF-g) <italic>in vitro</italic> (<xref ref-type="bibr" rid="R28">Kotz et al., 2010</xref>). Note: Sample data from this dataset did not pass our QC criteria. However, RNA Integrity Number (RIN) data were reported to be in the range of 7.4– 9.9, excluding RNA degradation, while comparison with neutrophils from GSE72642 showed a similar STP activity profile; for these reasons the dataset analysis was included.</p>
</list-item>
<list-item>
<p id="P23">GSE38351. Monocytes, isolated from peripheral blood of healthy individuals, resting and activated for 1.5 hour by incubation with TNFα, IFNα2a and IFNγ <italic>in vitro</italic> (<xref ref-type="bibr" rid="R46">Smiljanovic et al., 2012</xref>).</p>
</list-item>
<list-item>
<p id="P24">GSE43596. Monocytes isolated from peripheral blood of healthy volunteers were differentiated to macrophages, resting and activated by incubation for 2 hours with LPS (100 ng/mL) <italic>in vitro</italic> (<xref ref-type="bibr" rid="R33">Lowe et al., 2014</xref>).</p>
</list-item>
<list-item>
<p id="P25">GSE71566. CD4+ T cells derived from cord blood, resting or activated with anti-CD23/CD28 and differentiated towards respectively T-helper-1 (Th1) (incubation for 72 hrs with 2.5 ng/ml IL12 and Th2 neutralizing antibody anti-IL4, 1 μg/ml) and T-helper-2 (Th2) (10 ng/ml IL4 plus Th1 neutralizing antibody anti-interferon γ, 1 μg/ml) phenotype <italic>in vitro</italic> (<xref ref-type="bibr" rid="R26">Kanduri et al., 2015</xref>).</p>
</list-item>
<list-item>
<p id="P26">GSE63129. CD8+ T cells isolated from healthy individuals, activated by specific antigen, and immune-suppressed by presence of Treg cells <italic>in vitro</italic> (<xref ref-type="bibr" rid="R35">Maeda et al., 2014</xref>)</p>
</list-item>
<list-item>
<p id="P27">GSE39411. B cells, isolated from peripheral blood of healthy individuals, resting and activated for 1 hr and 3 hrs with anti-IgM<italic>, in vitro</italic> (<xref ref-type="bibr" rid="R50">Vallat et al., 2013</xref>).</p>
</list-item>
<list-item>
<p id="P28">GSE18791. Monocytes were isolated from healthy donors and differentiated to dendritic cells. Dendritic cells were activated by infection with Newcastle disease virus (NDV) <italic>in vitro</italic> (<xref ref-type="bibr" rid="R59">Zaslavsky et al., 2010</xref>).</p>
</list-item>
<list-item>
<p id="P29">GSE65010. Clinical study. Treg and Teffector cells (naïve and memory), isolated from peripheral blood of healthy individuals and RA patients (<xref ref-type="bibr" rid="R55">Walter et al., 2016</xref>)</p>
</list-item>
<list-item>
<p id="P30">GSE93272. Clinical study. Whole blood samples from healthy donors and RA patients. (<xref ref-type="bibr" rid="R49">Tasaki et al., 2018</xref>). Only Sample data from patients without treatment were used.</p>
</list-item>
</list>
</p>
</sec>
<sec id="S10">
<title>Privacy</title>
<p id="P31">All analyzed data were obtained in agreement with GDPR regulations, as implemented within Philips.</p>
</sec>
<sec id="S11">
<title>General rules for interpretation of signal transduction pathway activity score (PAS)</title>
<p id="P32">An important and unique advantage of the pathway activity assays is that in principle they can be performed on each cell type. A few considerations to bear in mind when interpretating log2 odds PAS, as described before (<xref ref-type="bibr" rid="R48">van de Stolpe et al., 2019</xref>): <list list-type="simple" id="L2">
<list-item>
<label>1)</label>
<p id="P33">On the same sample, log2 odds PAS cannot be compared between different STPs, since each STP has its own range in log2 odds activity scores (<xref ref-type="bibr" rid="R48">van de Stolpe et al., 2019</xref>)</p>
</list-item>
<list-item>
<label>2)</label>
<p id="P34">The log2 odds range for STP activity (minimum to maximum activity) may vary depending on cell type. Once the range has been defined using samples with known STP activity, on each new sample the absolute value can be directly interpreted against that reference. If the range has not been defined, only differences in log2 odds activity score between samples should be interpreted.</p>
</list-item>
<list-item>
<label>3)</label>
<p id="P35">PAS are highly quantitative, and even small differences in log2 odds PAS can be reproducible and meaningful.</p>
</list-item>
<list-item>
<label>4)</label>
<p id="P36">A negative log2 odds ratio does not necessarily mean that the STP is inactive.</p>
</list-item>
</list>
</p>
</sec>
<sec id="S12">
<title>Statistics</title>
<p id="P37">T-tests (unpaired, two-sided) were performed to compare pathway activity scores across groups. In case another statistical method was more appropriate due to the content of a specific dataset, this is indicated in the legend of the respective figure. Pearson correlation tests were performed. Exact p-values are indicated in the figures. P&lt;0.01 was considered significant (<xref ref-type="bibr" rid="R3">Amrhein et al., 2019</xref>). For studies with sample numbers n&lt;3, descriptive analysis was performed and no I-PAP was included in the tables (NK cells, CD8+ T cells). For <xref ref-type="table" rid="T1">Tables 1</xref>-<xref ref-type="table" rid="T4">4</xref> (I-PAPs), STPs were included for which the PAS difference was statistically significant. Underneath figures tables are shown in which numbered sample groups are compared using a t-test, deltas indicate the absolute measured difference in PAS between the compared sample groups, for every STP.</p>
</sec>
</sec>
</sec>
<sec id="S13" sec-type="results">
<title>Results</title>
<p id="P38">The immune response is determined by controlled activity of immune cells that are part of the innate and adaptive immune system, with the dendritic cell as the most powerful antigen-presenting cell bridging the two parts of the immune system (<xref ref-type="fig" rid="F1">Figure 1A</xref>) (<xref ref-type="bibr" rid="R13">Davis, n.d.</xref>). To define I-PAPs associated with the functional activity state of these immune cell types, STP activity analysis (AR, ER, PI3K-FOXO, MAPK, JAK-STAT1/2, JAK-STAT3, NFκB, TGFβ, Notch pathways) was performed on data from studies in which the respective immune cells were derived from healthy donors and activated <italic>in vitro</italic> in a controlled manner.</p>
<sec id="S14">
<title>STP analysis of primary immune cells isolated form blood</title>
<sec id="S15">
<title>Naïve/Resting state I-PAP of Monocyte, polymorphonuclear neutrophils (PMN), B cells, CD4+ and CD8+ T cells, NK cells (<xref ref-type="table" rid="T1">Table 1A</xref>, <xref ref-type="fig" rid="F2">Figure 2A</xref>)</title>
<p id="P39">Signaling pathway activities of resting immune cells were more similar between different healthy individuals (n=3) than between the different blood cell types. Myeloid (PMN, monocytes) and lymphoid (B and T cells) blood cell lineages could be easily distinguished; within the two lineages I-PAP profiles were more similar than between the lineages. Compared to lymphoid cells, myeloid cell types (monocytes and polymorphonuclear neutrophils) had higher FOXO PAS, reflecting lower activity of the PI3K growth factor pathway, and higher MAPK-AP1 and NFκB PAS; lymphoid cell types showed higher PI3K pathway activity (lower FOXO PAS) (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Within the lineages, cell types showed variations in STP activity, defining their I-PAP (<xref ref-type="fig" rid="F2">Figure 2A</xref>). For the lymphoid lineage (high PI3K pathway activity) B cells had highest JAK-STAT1/2 PAS, CD4+ T cells highest JAK-STAT3 PAS, NK cells by highest TGFβ PAS, and CD8+ T cells lowest NFκB PAS. For the myeloid lineage (high MAPK, NFκB pathwya activity), neutrophils has higher NFκB, JAK-STAT3, and TGFβ PAS than monocytes (<xref ref-type="fig" rid="F2">Figure 2A</xref>).</p>
</sec>
<sec id="S16">
<title>Naïve and memory CD4+ T cells (<xref ref-type="fig" rid="F1">Figure 1B</xref>, <xref ref-type="table" rid="T1">Table 1B</xref>)</title>
<p id="P40">T cells change into memory T cells upon disappearance of the antigen, but they retain the memory to the antigen, enabling rapid activation upon renewed exposure to the specific antigen. Memory CD4+ T cells (both Treg and T effector) had lower PI3K pathway activity than naïve T cells, reflecting loss of division, and higher PAS for a number of STPs, including the TGFβ pathway (<xref ref-type="table" rid="T1">Table 1B</xref>, Treg/ Teffector).</p>
<p id="P41">While having an allmost identical I-PAP in the naïve state, memory Treg and Teffector cells could be clearly distinguished by higher NFκB and TGFβ PAS in Tregs (<xref ref-type="table" rid="T1">Table 1B</xref>, Treg specific) and higher AR, ER and MAPK PAS in Teffector cells (<xref ref-type="table" rid="T1">Table 1B</xref>, T effector specific).</p>
</sec>
<sec id="S17">
<title>Dendritic cells (<xref ref-type="table" rid="T1">Table 1C</xref>, <xref ref-type="fig" rid="F2">Figure 2C</xref>)</title>
<p id="P42">Dendritic cells function as master regulators of the immune response. Blocking functional activation results in immunosuppression, as for example seen in cancer and certain viral infections. Plasmacytoid (pDC) and myeloid (mDC) DC subsets recognize different pathogens and activate innate and adaptive immune response in a specific manner. pDC precursors produce type I interferons in response to viruses and can activate mDCs.</p>
<p id="P43">In line with their different functions, plasmacytoid and myeloid dendritic cells (pDCs and mDCs) had different I-PAPs, with most prominent differences in the NFκB, AR, and JAK-STAT1/2 PAS.</p>
</sec>
</sec>
<sec id="S18">
<title>STP analysis of primary immune cells from blood, activated <italic>in vitro</italic>
</title>
<p id="P44">Following STP analysis of immune cells isolated from blood, we investigated changes in signaling pathway activity upon <italic>in vitro</italic> activation of immune cells.</p>
<sec id="S19">
<title>Cells of the innate immune response, Natural Killer cells</title>
<p id="P45">NK cells are part of the lymploid lineage but function in the innate immune response as cyotoxic cells that kill cells that do not express the correct Major Histocompatibility Complex (MHC) signature.</p>
<p id="P46">Primary NK cells had been activated <italic>in vitro</italic> with both a low and high dose interferon α. The low sample number only allows a descriptive analysis. Compared to control incubation, activation resulted dose-dependently in reduced PI3K (increased FOXO PAS), NFκB and Notch pathway activity, and increased JAK-STAT pathway activity (JAK-STAT1/2 and JAK-STAT3 PAS) (<xref ref-type="fig" rid="F3">Figure 3A</xref>).</p>
</sec>
<sec id="S20">
<title>Cells of the innate immune response, Neutrophils (<xref ref-type="fig" rid="F3">Figure 3B</xref>, <xref ref-type="table" rid="T2">Table 2</xref>)</title>
<p id="P47">Neutrophils phagocytose pathogens and mediate important inflammatory reactions within the innate immune response.</p>
<p id="P48">Activation of neutrophils with LPS or with granulocyte-macrophage colony-stimulating factor (GM-CSF) plus interferon-gamma (INF-γ) resulted in activation of a number of shared STPs (<xref ref-type="table" rid="T2">Table 2</xref>, <italic>I-PAP activated cells</italic>). In addition to these changes, LPS specifically induced MAPK pathway activity. Of all investigated immune cell types, activated neutrophils had highest TGFβ PAS.</p>
</sec>
<sec id="S21">
<title>Cells of the innate immune response, Monocytes (<xref ref-type="fig" rid="F3">Figure 3C, 3D</xref>, <xref ref-type="table" rid="T2">Table 2</xref>)</title>
<p id="P49">Monocytes are the circulating precursor cells of tissue macrophages, and home to tissue locations to infiltrate and differentiate to tissue macrophages. Monocyte activation-induced JAK-STAT1/2 pathway activity PAS have been reported before and have been included here to enable determination of the complete monocyte I-PAP (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>).</p>
<p id="P50">Brief <italic>in vitro</italic> incubation itself induced a small increase in NFκB and JAK-STAT3 PAS. Compared with this control state, activation with TNFα, interferon type I (IFN-α2a), or interferon type II (IFN-γ) induced activity of shared STPs (<italic>
<xref ref-type="table" rid="T2">Table 2</xref>, monocytes, shared activated pathways</italic>), while in addition STPs were specifically activated by TNFα and the two types of interferon (<xref ref-type="table" rid="T2">Table 2</xref>, TNFα, specific activated pathways; interferon, specific activated pathways). While activation with TNFα or either type of interferon resulted in a comparable induction of JAK-STAT3 PAS, the large increase in JAK-STAT1/2 PAS was specific for activation with interferons (delta in log 2 odds: 1.4 for TNFα and 22 for interferons), (<xref ref-type="fig" rid="F3">Figure 3D</xref>). Interferons are specific activators of the JAK-STAT1/2 pathway (<xref ref-type="bibr" rid="R42">Platanias, 2005</xref>)</p>
</sec>
<sec id="S22">
<title>Cells of the innate immune response, Macrophages (<xref ref-type="fig" rid="F3">Figure 3E</xref>) (<xref ref-type="table" rid="T2">Table 2</xref>)</title>
<p id="P51">Activation with LPS resulted in a reduction in growth factor pathway activity (both PI3K and MAPK pathways) and increased NFκB, JAK-STAT3, TGFβ, and Notch PAS. This I-PAP was comparable with the I-PAP of LPS-stimulated neutrophils, except for higher TGFβ PAS in neutrophils (compare <xref ref-type="fig" rid="F3">Figure 3E with 3B</xref>).</p>
</sec>
<sec id="S23">
<title>Cells of the adaptive immune response, CD4+ T cells</title>
<p id="P52">CD4+ T cells regulate activity of CD8+ T cells and B cells and can differentiate towards specific T helper cells. The Th1 type supports the cell-mediated immune response and helps cytotoxic T cells while Th2 cells mainly help B cells in their humoral (antibody) immune response.</p>
<p id="P53">Except for ER, AR, and MAPK PAS, pathway analysis results of CD4+ T cells and Th1 and Th2 cells have been reported before, and are presented to enable determination of a complete I-PAP (<xref ref-type="bibr" rid="R57">Wesseling-Rozendaal et al., 2020</xref>)(<xref ref-type="fig" rid="F4">Figure 4A</xref>, <xref ref-type="table" rid="T3">Table 3</xref>). Differentiation of activated CD4+ T cells to lymphocyte subtypes Th1 and Th2 resulted in opposite changes in NFκB PAS: increased NFκB pathway activity in Th1, and decreased activity in Th2. Incubation of activated CD4+ T cells with an antibody against interferon-γ was used to induce Th2 cell differentiation <italic>in vitro</italic>, and this resulted in the expected reduction in PAS for the interferon-inducible JAK-STAT1/2 pathway.</p>
</sec>
<sec id="S24">
<title>Cells of the adaptive immune response, CD8+ T cells (n&lt;3, descriptive interpretation, <xref ref-type="fig" rid="F4">Figure 4B</xref>)</title>
<p id="P54">CD8+ T cells are cytotoxic T cells that attack cells upon specific antigen recognition.</p>
<p id="P55">For specific antigen-induced immune-activated CD8+ T cells, data from one healthy individual were available, allowing only a tentative and descriptive I-PAP. Antigen-specific activation (compared to non-antigen-specific activation) was associated with higher PI3K (lower FOXO PAS) pathway activity, reflecting T cell proliferation, and lower NFκB, TGFβ, and Notch PAS; in the presence of immunosuppressive Treg cells, PI3K PAS was lower and NFκB PAS decreased further.</p>
</sec>
<sec id="S25">
<title>Cells of the adaptive immune response, B cells (<xref ref-type="fig" rid="F4">Figure 4C</xref>, <xref ref-type="table" rid="T3">Table 3</xref>)</title>
<p id="P56">B cell produce IgM and IgG antibodies directed towards specific antigens. Activation of B cells with IgM antibody resulted in an I-PAP with a notably increased Notch PAS, only equalled by LPS-induced Notch PAS in neutrophils and macrophages, and increased JAK-STAT pathway activity (both JAK-STAT1/2 and JAK-STAT3). (<xref ref-type="table" rid="T3">Table 3</xref>, <xref ref-type="fig" rid="F4">Figure 4D</xref>).</p>
</sec>
</sec>
<sec id="S26">
<title>Dendritic cells (<xref ref-type="fig" rid="F5">Figure 5</xref>, <xref ref-type="table" rid="T2">Table 2</xref>)</title>
<p id="P57">
<italic>In vitro</italic> infection with the Newcastle Disease virus has been developed as a model system for <italic>in vivo</italic> DC maturation (<xref ref-type="bibr" rid="R59">Zaslavsky et al., 2010</xref>). Within two hours after viral infection NFκB PAS increased, followed at four hours by an increase in JAK-STAT1/2 PAS and after 10 hours by moderately increased TGFβ PAS (p=0.01). This is a logical orde of pathway activation since the NFκB pathway is required for antigen processing; NFκB-induced production of interferons is responsible for activation of the JAK-STAT1/2 pathway, necessary for antigen presentation (<xref ref-type="bibr" rid="R4">Barber, 2015</xref>); the final activation of the TGFβ pathway probably enables migration of the antigen-presenting DCs to the lymph node (<xref ref-type="bibr" rid="R5">Batlle and Massagué, 2019</xref>).</p>
</sec>
</sec>
<sec id="S27">
<title>Reproducibility of STP PAS</title>
<sec id="S28">
<title>Comparison of pathway activity scores between samples from different healthy donors</title>
<p id="P58">In the datasets in which cells were obtained from multiple healthy donors, there was a remarkable consistency in STP PAS between individual donors, both for resting and activated immune cell types, suggesting tight control of functional processes in the immune response (<xref ref-type="fig" rid="F2">Figure 2</xref>-<xref ref-type="fig" rid="F5">5</xref>).</p>
</sec>
<sec id="S29">
<title>Comparison of I-PAP of freshly isolated immune cells with cells incubated <italic>in vitro</italic>
</title>
<p id="P59">The absolute pathway PAS of immune cells kept for a number of hours <italic>in vitro</italic> differed from the I-PAP identified for primary cells directly analyzed after isolation from peripheral blood, probably under the influence of variations in the composition of the incubation medium (e.g. concentration of growth factors that activate the PI3K pathway) or incubation time, (compare <xref ref-type="fig" rid="F3">Figure 3</xref>,<xref ref-type="fig" rid="F4">4</xref> with <xref ref-type="fig" rid="F2">Figure 2</xref> and <xref ref-type="supplementary-material" rid="SD1">S1</xref>).</p>
</sec>
<sec id="S30">
<title>Reproducibility of I-PAPs across independent studies</title>
<p id="P60">To confirm the I-PAPs for the various immune cell types, we tried to analyze an independent second dataset for the same cell type (<xref ref-type="supplementary-material" rid="SD1">Figures S2-5</xref> in the supplement). This was not possible for all immune cell types (lack of available studies with the required sample data or in case of neutrophil datasets due to QC failure for Affymetrix data). Overall, I-PAPs were comparable between independent datasets and similar relative differences in pathway activities between resting and activated cells were found, despite studies having been performed in different laboratories under different conditions (compare <xref ref-type="fig" rid="F2">figures 2</xref>-<xref ref-type="fig" rid="F5">5</xref> with <xref ref-type="supplementary-material" rid="SD1">S1-S6</xref>). However, I-PAP differences were found between independent datasets for a specific immune cell type which were probably caused by different activation protocols, for example, NK cells were either stimulated with IFNα for six hours and compared with control culture medium for the same time period (<xref ref-type="fig" rid="F3">Figure 3A</xref>), or stimulated with IL2 in culture medium for 24 hours without an incubation-time control sample, or with a coctail of IL-2, IL-12, IL-18 for 24 hours (<xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>).</p>
<p id="P61">Analysis of the various immune cell types in a resting state, directly from peripheral blood samples, also showed consistent results between two independent datasets (compare <xref ref-type="fig" rid="F2">Figure 2</xref> with <xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>). Besides illustrating reproducibility of the STP assay technology, this provides consistent evidence for the roles of signaling pathways in controlling immune cell functions.</p>
<sec id="S31">
<title>Summary on I-PAPs of lymphocyte and monocytic lineage cell types in resting versus immune-activated functional state</title>
<p id="P62">With respect to growth factor pathways MAPK and PI3K (responsible for cell division), comparing immune cells from the myeloid (neutrophils, monocytes, macrophages, and dendritic cells) with the lymphoid lineage (NK cells; CD4+ T cells, CD8+ T cells, B cells) in a resting state, suggests the MAPK pathway as the dominant growth factor pathway in myeloid-derived cells, and the PI3K pathway in lymphoid cells (<xref ref-type="table" rid="T1">Table 1</xref>). Between lineage subtypes additional variations in activity of these growth factor pathways was found, e.g. myeloid derived DCs had a higher MAPK pathway activity than their plasmacytoid counterpart (<xref ref-type="table" rid="T1">Table 1C</xref>) and memory Treg cells typically had lower PI3K PAS scores compared to their naïve counterpart (<xref ref-type="table" rid="T1">Table 1B</xref>).</p>
<p id="P63">In line with a (cell division) role for the PI3K pathway in lymphoid lineage cells, with the exception of NK cells, immune activation was associated with PI3K pathway activation in CD4+ T cells, CD8+ T cells, and B cells (unpaired t-test not significant, paired t-test two sided, p=0.009343), and PI3K pathway activity was also higher in naïve compared to memory (CD4+) T cells (<xref ref-type="table" rid="T4">Table 4</xref>, <xref ref-type="table" rid="T1">Table 1</xref>). In myeloid cells growth factor pathway activity did not change upon cell activation.</p>
<p id="P64">TGFβ pathway activity was inversely related to immune activation in lymphoid cell types, but associated with immune activation in myeloid cell types. Immune-activation of CD4+ T cells (and CD8+ T cells, n&lt;3) was associated with reduced TGFβ pathway activity and memory T cells had higher TGFβ PAS than naïve T cells (<xref ref-type="table" rid="T1">Table 1</xref>). This role of the TGFβ pathway was in line with our earlier observations in activated CD4+ T cells that became tolerogenic upon exposure to breast cancer supernatant, associated with a marked increase in TGFβ pathway activity (<xref ref-type="bibr" rid="R57">Wesseling-Rozendaal et al., 2020</xref>). In contrast, in cells of the myeloid lineage, immune activation was associated with increased TGFβ PAS, to much higher values than in lymphoid cells (<xref ref-type="table" rid="T2">Table 2</xref>,<xref ref-type="table" rid="T3">3</xref>, <xref ref-type="fig" rid="F3">Figures 3</xref>,<xref ref-type="fig" rid="F4">4</xref>).</p>
<p id="P65">NFκB PAS scores were higher in myeloid cells than lymphoid cells, and increased strongly upon activation with highest absolute scores in neutrophils.</p>
<p id="P66">The JAK-STAT pathways seemed to play a role in activation of both myeloid and lymphoid cell types, although the JAK-STAT3 pathway activity seemed more prominent in myeloid cells.</p>
<p id="P67">(<xref ref-type="table" rid="T2">Table 2</xref>,<xref ref-type="table" rid="T3">3</xref>).</p>
<p id="P68">For many signaling pathways, including NFκB and TGFβ, activation was variable across the different cell types and their functional state, suggesting different functions for these pathways, depending on cellular context.</p>
</sec>
<sec id="S32">
<title>Exploration of clinical value: STP analysis of a clinical study on RA</title>
<p id="P69">Quantifying the immune response state based on blood sampling may find clinical utility in predicting and monitoring response to signaling pathway-targeted therapy (such as TNFα and JAK inhibitors) in auto-immune diseases like rheumatoid arthritis, among other applications.</p>
<p id="P70">We analyzed two clinical studies on rheumatoid arthritis (RA) for which blood sample data were available (<xref ref-type="bibr" rid="R55">Walter et al., 2016</xref>),(<xref ref-type="bibr" rid="R49">Tasaki et al., 2018</xref>). In whole blood samples TGFβ PAS was increased in both male and female RA patients, while increased JAK-STAT3 PAS reached significance in the female patient group. Many immune cell types may contribute to increased TGFβ and JAK-STAT3 PAS measured in whole blood. The second study allowed analysis of CD4+ naïve, memory Treg and T effector cells of RA patients (<xref ref-type="bibr" rid="R55">Walter et al., 2016</xref>). TGFβ PAS was higher in naïve Tregs of RA patients (p=0.016), while activity of the JAK-STAT3 pathway tended to increase in memory T effector cells of patients with RA (n=6, p=0.065, <xref ref-type="fig" rid="F6">Figure 6</xref>), suggesting that these cell types contributed to the STP analysis results in whole blood samples, and may play a role in the pathogenesis of the disease.</p>
</sec>
<sec id="S33">
<title>Comparison of STP analysis with conventional Affymetrix data analysis</title>
<p id="P71">We compared our STP analysis results with the data analysis results reported in the publications associated with the public datasets (Supplementary information). Publicly available tools had been used to analyze the data, and comparison between sample groups revealed group-associated gene profiles and suggestions for differential involvement of cellular processes (not the same as signal transduction pathways). In contrast to the here presented STP analysis on single sample data, no results on analysis of individual patient samples were provided.</p>
</sec>
</sec>
</sec>
<sec id="S34" sec-type="discussion">
<title>Discussion</title>
<p id="P72">STP activity profiling of the different immune cell types revealed characteristic I-PAPs for each cell type in a resting and immune-activated state. Each I-PAP consists of combined quantitative pathway activity scores of the ER, AR, PI3K, MAPK, NFκB, JAK-STAT1/2, JAK-STAT3, TGFβ and Notch pathways. For some immune cell types more than one independent dataset was available for analysis, with largely similar results, providing support for reproducibility of the I-PAPs. This is the first time that immune cells have been characterized by means of activity of nine major STPs that determine their function. All used STP assays have been validated before on multiple cell types for which pathway activity was known, supporting their use on different cell types including blood cells (<xref ref-type="bibr" rid="R54">Verhaegh et al., 2014</xref>), (<xref ref-type="bibr" rid="R53">van Ooijen et al., 2018</xref>), (<xref ref-type="bibr" rid="R48">Stolpe et al., 2019</xref>), (<xref ref-type="bibr" rid="R9">Canté-Barrett et al., 2020</xref>), (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>), (<xref ref-type="bibr" rid="R57">Wesseling-Rozendaal et al., 2020</xref>). The remarkable similarity in pathway activities found between samples of healthy donors suggests strict regulation of signaling pathway activity and associated functional states of immune cells, in line with their important function in orchestrating immune responses.</p>
<p id="P73">Myeloid and lymphoid-derived cell types differed in their pathway activity profile, reflecting functional differences. While the PI3K growth factor pathway was more active in lymphocyte cell types, in myeloid derived cell types the MAPK growth factor pathway was most active, in combination with NFκB, TGFβ, and JAK-STAT3 pathways, in line with lineage-specific immune functions (<xref ref-type="bibr" rid="R11">Cantrell, 2015</xref>), (<xref ref-type="bibr" rid="R38">Newton and Dixit, 2012</xref>), (<xref ref-type="bibr" rid="R45">Shuai and Liu, 2003</xref>). The multiple pathway activity in myeloid cells is likely to reflect crosstalk between these signaling pathways (<xref ref-type="bibr" rid="R12">Chen and Ten Dijke, 2016</xref>),(<xref ref-type="bibr" rid="R34">Luo, 2017</xref>),(<xref ref-type="bibr" rid="R45">Shuai and Liu, 2003</xref>).</p>
<p id="P74">For a number of STPs specific functions in immune cells have been described, although generally not based on actual measurement of pathway activity but based on the expression levels of either ligands, receptors, or transcription factors associated with the pathway (e.g., see (<xref ref-type="bibr" rid="R25">Janghorban et al., 2018</xref>), (<xref ref-type="bibr" rid="R5">Batlle and Massagué, 2019</xref>). Our observation that PI3K activity in CD4+ and CD8+ T cells increased upon activation is in line with the role of this pathway to induce clonal proliferation of activated T cells, (<xref ref-type="bibr" rid="R24">Han et al., 2012</xref>). The observed inverse relationship of TGFβ pathway activity with CD4+ and CD8+ T cell activation supports our earlier findings that this pathway becomes active in CD4+ T cells upon exposure to breast cancer supernatant, inducing immunotolerance (<xref ref-type="bibr" rid="R57">Wesseling-Rozendaal et al., 2020</xref>). The immunosuppressive role of the TGFβ pathway in diseases such as cancer is well known (<xref ref-type="bibr" rid="R31">Li et al., 2007</xref>), (<xref ref-type="bibr" rid="R58">Yang, 2015</xref>),(<xref ref-type="bibr" rid="R5">Batlle and Massagué, 2019</xref>). Also, TGFβ pathway activity in neutrophils and macrophages is held responsible for inflammatory and tumor promoting functions (<xref ref-type="bibr" rid="R18">Futosi et al., 2013</xref>),(<xref ref-type="bibr" rid="R17">Fridlender et al., 2009</xref>), (<xref ref-type="bibr" rid="R2">Allavena et al., 2008</xref>).</p>
<p id="P75">The strong activation of the NFκB pathway induced by LPS and TNFα in myeloid cells, highlights the prominent role of this pathway as mediator of inflammatory immune responses by monocytes and neutrophils (<xref ref-type="bibr" rid="R38">Newton and Dixit, 2012</xref>),(<xref ref-type="bibr" rid="R60">Zhang et al., 2017</xref>). On the other hand, changes in NFκB pathway activity in lymphoid cells are more likely associated with other immune functions of this pathway, such as regulation of cell division, migration, antigen processing, and apoptosis, dependent on cellular context (<xref ref-type="bibr" rid="R38">Newton and Dixit, 2012</xref>), (<xref ref-type="bibr" rid="R60">Zhang et al., 2017</xref>).</p>
<p id="P76">The MAPK and Notch pathways have multiple context-dependent functions in the innate and adaptive immune response, and are involved in immune cell differentiation (<xref ref-type="bibr" rid="R15">Dong et al., 2002</xref>),(<xref ref-type="bibr" rid="R25">Janghorban et al., 2018</xref>). MAPK pathway activity was higher in Th1 than Th2 cells, in agreement with its involvement in Th1 differentiation (<xref ref-type="bibr" rid="R15">Dong et al., 2002</xref>). The high Notch pathway activity measured in B cells compared to T cells reflects its T cell-suppressing role in differentiation (<xref ref-type="bibr" rid="R25">Janghorban et al., 2018</xref>). Highest Notch pathway activity was associated with LPS and interferon-mediated activation of myeloid cell types, supportive of the role for this pathway in inflammatory responses (<xref ref-type="bibr" rid="R19">Gamrekelashvili et al., 2020</xref>).</p>
<p id="P77">We found the JAK-STAT pathways to be involved in many functional immune cell changes, in agreement with their distinct roles in a variety of immune reactions, dependent on cellular context. JAK-STAT1/2 pathway activity was generally induced by the presence of interferons, which are the typical ligands to activate this pathway (<xref ref-type="bibr" rid="R45">Shuai and Liu, 2003</xref>), (<xref ref-type="bibr" rid="R4">Barber, 2015</xref>). Indeed, we reported before increased JAK-STAT1/2 pathway activity in peripheral blood mononuclear cell (PBMC) samples during viral infections, known to be associated with strong interferon production (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>). In the same study, JAK-STAT3 pathway activity increased selectively in PBMCs of patients with clinically severe infection and also after Bacillus Calmette-Guérin (BCG) boost vaccination (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>). The current finding that JAK-STAT3 pathway activity was highest in activated cells of the monocytic lineage suggests that these cells were responsible for the earlier finding. We hypothesize that JAK-STAT3 pathway activity in monocytes (and macrophages) may reflect “trained immunity” which is associated with a strong inflammatory component; enabling direct measurement of this immune mechanism in patients (<xref ref-type="bibr" rid="R37">Netea et al., 2020</xref>), (<xref ref-type="bibr" rid="R36">Mulder et al., 2019</xref>).</p>
<p id="P78">AR pathway activity also increased in activated monocytes, in line with our earlier reporting on increased AR pathway activity in blood samples of patients with bacterial sepsis, in which monocytes play a dominant role (<xref ref-type="bibr" rid="R8">Bouwman et al., 2021</xref>), (<xref ref-type="bibr" rid="R43">Reyes et al., 2020</xref>). For the ER pathway low activity scores were consistently measured, with the only difference found between plasmacytoid and myeloid dendritic cells. Indeed, for both nuclear receptor (AR and ER) pathways, evidence is available for involvement in the innate immune response, with an immunosuppressive role for the AR pathway and a still controversial role for the ER pathway (<xref ref-type="bibr" rid="R29">Kovats, 2015</xref>), (<xref ref-type="bibr" rid="R23">Gubbels Bupp and Jorgensen, 2018</xref>), (<xref ref-type="bibr" rid="R30">Lai et al., 2012</xref>).</p>
<p id="P79">As referred to before, depending on cellular context individual STPs may crosstalk to involve other STPs to orchestrate the immune response. One way in which this may happen is illustrated by our time-related analysis of dendritic cell activation: viral infection sequentially activated the NFκB, JAK-STAT1/2, and finally the TGFβ pathway. The NFκB pathway is activated by the intracellular STING pathway to enable antigen processing, and subsequently induces production of interferons to activate the JAK-STAT1/2 pathway, necessary for presentation of antigens, while finally activating the TGFβ pathway, probably enabling DC migration (<xref ref-type="bibr" rid="R4">Barber, 2015</xref>),(<xref ref-type="bibr" rid="R34">Luo, 2017</xref>).</p>
<sec id="S35">
<title>Analysis of samples from patients with rheumatoid arthritis</title>
<p id="P80">In whole blood samples from patients with RA, activity of the TGFβ pathway and the JAK-STAT3 pathway were increased. Since whole blood consists of a mixture of cell types, these results are not directly informative on the functional activity state of the different immune cell types in the whole blood sample. Pathway analysis of a second clinical RA study (Treg and T effector cell samples) showed that at least the Treg cell population has abnormal STP activity: TGFβ pathway activity was higher in naïve Tregs, while JAK-STAT3 pathway tended to be more active in memory Tregs. Interesting, the investigators who generated the Affymetrix data of this study used Qlucore Omics Explorer software for the Affymetrix data analysis and concluded that no defect could be found in the Treg and T effector cells of the RA patients (<xref ref-type="bibr" rid="R55">Walter et al., 2016</xref>). However, both signaling pathways which we identified are known to play a pathogenic role in rheumatoid arthritis, and components of the JAK-STAT3 pathway (including its activating ligand IL-6) are important RA drug targets (<xref ref-type="bibr" rid="R6">Bottini et al., 2019</xref>), (<xref ref-type="bibr" rid="R44">Scott et al., 2010</xref>). The pro-inflammatory cytokine IL-6 and the immunosuppressive TGFβ together control differentiation between proinflammatory Th17 and immunosuppressive Treg cells, where IL-6 directs the balance towards Th17 cells by activating the JAK-STAT3 pathway, while TGFβ switches the balance towards Treg cells by activating the TGFβ pathway (<xref ref-type="bibr" rid="R27">Kimura and Kishimoto, 2010</xref>). Although insufficient to reveal the exact mechanism, we hypothesize that our findings reflect a disturbance in this balance, in favor of an inflammatory state. The variation in STP activity found in the RA patients suggests that the pathogenic mechanism varies among individual RA patients, suggesting that a personalized treatment approach is needed to provide the most effective treatment. Clinical use of our pathway assays may lie in diagnosis and monitoring of patients with RA, and in therapy response prediction: for example patients with high JAK-STAT3 pathway activity may be more likely to respond to JAK-STAT3 pathway inhibitors than patients with a JAK-STAT3 pathway activity in the normal range.</p>
</sec>
<sec id="S36">
<title>Comparison of STP data analysis with conventionally used Affymetrix data analysis tools</title>
<p id="P81">We have shown in the current study that we can extract relevant biological information from transcriptome data that was not discovered by conventional data analysis, similar to our previous reports (<xref ref-type="bibr" rid="R54">Verhaegh et al., 2014</xref>), (<xref ref-type="bibr" rid="R52">van de Stolpe et al., 2021</xref>),(<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>), (<xref ref-type="bibr" rid="R57">Wesseling-Rozendaal et al., 2020</xref>),(<xref ref-type="bibr" rid="R8">Bouwman et al., 2021</xref>). Data analysis tools, such as GSEA and Ingenuity Pathway Analysis, provide differential involvement of all kinds of cellular processes when comparing two groups of samples and are suited for biomarker discovery. Our STP analysis is specifically designed to quantitatively measure STP activities (for a defined set of STPs) on an individual sample, for example for diagnostic purposes or to gain insight in immune cell biology.</p>
</sec>
<sec id="S37">
<title>STP analysis in perspective</title>
<p id="P82">We expect that measuring STP activity will enable functional quantification of the innate and adaptive immune response on blood samples of individual patients, or of a selected immune cell type. There are many clinically relevant diagnostic applications that can be developed, such as: (1) prediction and monitoring of response to cancer immunotherapy (see our publication (<xref ref-type="bibr" rid="R57">Wesseling-Rozendaal et al., 2020</xref>)), (2) differential diagnosis of viral versus bacterial infection, (see our publication (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>)), (3) assessment and monitoring of the severity of a viral infection (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>), (4) prediction of risk at development of sepsis in a patient with a bacterial infection, sepsis diagnosis and prognosis and prediction of treatment response (see our publication (<xref ref-type="bibr" rid="R8">Bouwman et al., 2021</xref>)), (5) diagnosis and treatment response prediction for many immune-mediated diseases (unpublished results, e.g. for Crohn's Disease and Ulcerative Colitis, sarcoidosis, glomerulonephritis, psoriasis, pulmonary fibrosis); (6) prediction of late complications of kidney transplantation, such as fibrosis and glomerulonephritis (unpublished results). Determining and quantifying efficacy and side effects of vaccinations (see publication (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>)) is another interesting application. Finally it is expected to improve development of immunomodulatory drugs, for multiple reasons: (1) The technology enables easy quantification of the effect of a drug/compound on STPs that determine immune cell functions; (2) Quantitative comparison between <italic>in vitro</italic> disease models and the actual disease in the patient with respect to the STP activity profile, enables choice of disease models that best represent <italic>in vivo</italic> disease; (3) Many existing drugs (for example developed for cancer applications) target these STPs, making them prime candidates for repurposing as immunomodulatory drugs.</p>
<p id="P83">To enable future implementation, it is necessary to have STP assays with shorter time-to-result than the Affymetrix microarray; for this reason the assay platform has been converted to qPCR, enabling a result within a few hours (<ext-link ext-link-type="uri" xlink:href="http://www.philips.com/oncosignal)">www.philips.com/oncosignal)</ext-link>. Clinical implementation will also require establishment of normal ranges for STP PAS, which is likely to be possible given the similarity of I-PAPs for healthy individual samples, and earlier reported results (<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>), (<xref ref-type="bibr" rid="R8">Bouwman et al., 2021</xref>). Another challenge is the type of blood sample to analyze. We have shown previously that STP analysis of mixed immune cell type samples, such as PBMCs or whole blood, may already provide clinically relevant results for a number of applications (<xref ref-type="bibr" rid="R8">Bouwman et al., 2021</xref>),(<xref ref-type="bibr" rid="R7">Bouwman et al., 2020</xref>). However, detailed analysis of the immune response of an individual will require isolation of specific immune cells of interest. While a single measurement can be directly informative, repeated analysis may add clinically relevant information by quantitative monitoring of changes in immune response.</p>
</sec>
<sec id="S38" sec-type="conclusions">
<title>Conclusion</title>
<p id="P84">We have developed a new STP assay technology for quantitative measurement of the functional activity state of myeloid and lymphoid cell types, enabling for the first time characterization of the immune response in a patient sample and <italic>in vitro</italic>.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplemental information</label>
<media xlink:href="EMS136379-supplement-Supplemental_information.pdf" mimetype="application" mime-subtype="pdf" id="N67164" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn id="FN2" fn-type="conflict">
<p id="P85">
<bold>Conflict of interest statement</bold>
</p>
<p id="P86">All authors are employees of Philips.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allantaz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Bergauer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ravindran</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rossier</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Ebeling</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Badi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bitter</surname>
<given-names>H</given-names>
</name>
<name>
<surname>D'Asaro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chiappe</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression</article-title>
<source>PLoS One</source>
<year>2012</year>
<volume>7</volume>
<elocation-id>e29979</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0029979</pub-id>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allavena</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sica</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garlanda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mantovani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance</article-title>
<source>Immunol Rev</source>
<year>2008</year>
<volume>222</volume>
<fpage>155</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00607.x</pub-id>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amrhein</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Greenland</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McShane</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Scientists rise up against statistical significance</article-title>
<source>Nature</source>
<year>2019</year>
<volume>567</volume>
<fpage>305</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1038/d41586-019-00857-9</pub-id>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barber</surname>
<given-names>GN</given-names>
</name>
</person-group>
<article-title>STING: infection, inflammation and cancer</article-title>
<source>Nat Rev Immunol</source>
<year>2015</year>
<volume>15</volume>
<fpage>760</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="doi">10.1038/nri3921</pub-id>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batlle</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Massagué</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Transforming Growth Factor-β Signaling in Immunity and Cancer</article-title>
<source>Immunity</source>
<year>2019</year>
<volume>50</volume>
<fpage>924</fpage>
<lpage>940</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.024</pub-id>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bottini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Ai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Le Roux</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bartok</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bombardieri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Doody</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sacchetti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zoccheddu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lonic</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>PTPN14 phosphatase and YAP promote TGFβ signalling in rheumatoid synoviocytes</article-title>
<source>Ann Rheum Dis</source>
<year>2019</year>
<volume>78</volume>
<fpage>600</fpage>
<lpage>609</lpage>
<pub-id pub-id-type="doi">10.1136/annrheumdis-2018-213799</pub-id>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouwman</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Holtzer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Measurement of Cellular Immune Response to Viral Infection and Vaccination</article-title>
<source>Front Immunol</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>575074</elocation-id>
<pub-id pub-id-type="doi">10.3389/fimmu.2020.575074</pub-id>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouwman</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Androgen receptor pathway activity assay for sepsis diagnosis and prediction of favorable prognosis</article-title>
<source>medRxiv</source>
<year>2021</year>
<elocation-id>2021.07.07.21259768</elocation-id>
<pub-id pub-id-type="doi">10.1101/2021.07.07.21259768</pub-id>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canté-Barrett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Holtzer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van Ooijen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hagelaar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cordo'</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meijerink</surname>
<given-names>JPP</given-names>
</name>
</person-group>
<article-title>A Molecular Test for Quantifying Functional Notch Signaling Pathway Activity in Human Cancer</article-title>
<source>Cancers (Basel)</source>
<year>2020</year>
<volume>12</volume>
<pub-id pub-id-type="doi">10.3390/cancers12113142</pub-id>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="book">
<person-group person-group-type="editor">
<name>
<surname>Cantley</surname>
<given-names>Lewis C</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>Tony</given-names>
</name>
<name>
<surname>Sever</surname>
<given-names>Richar</given-names>
</name>
<name>
<surname>Thorner</surname>
<given-names>Jeremy W</given-names>
</name>
</person-group>
<source>Signal transduction : principles, pathways, and processes</source>
<publisher-loc>Cold Spring Harbor, New York</publisher-loc>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
<year>2014</year>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantrell</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Signaling in lymphocyte activation</article-title>
<source>Cold Spring Harb Perspect Biol</source>
<year>2015</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.1101/cshperspect.a018788</pub-id>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ten Dijke</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Immunoregulation by members of the TGFβ superfamily</article-title>
<source>Nat Rev Immunol</source>
<year>2016</year>
<volume>16</volume>
<fpage>723</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1038/nri.2016.112</pub-id>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>DM</given-names>
</name>
</person-group>
<source>The Beautiful Cure</source>
<date-in-citation>accessed 7.13.21</date-in-citation>
<comment>n.d. [WWW Document]. URL <ext-link ext-link-type="uri" xlink:href="https://www.penguin.co.uk/books/1109946/the-beautiful-cure/9781784702212">https://www.penguin.co.uk/books/1109946/the-beautiful-cure/9781784702212</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deftos</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Bevan</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Notch signaling in T cell development</article-title>
<source>Curr Opin Immunol</source>
<year>2000</year>
<volume>12</volume>
<fpage>166</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1016/s0952-7915(99)00067-9</pub-id>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>MAP kinases in the immune response</article-title>
<source>Annu Rev Immunol</source>
<year>2002</year>
<volume>20</volume>
<fpage>55</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.immunol.20.091301.131133</pub-id>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lit</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gregg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>FR</given-names>
</name>
</person-group>
<article-title>Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome</article-title>
<source>Genomics</source>
<year>2006</year>
<volume>87</volume>
<fpage>693</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygeno.2006.02.003</pub-id>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fridlender</surname>
<given-names>ZG</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Worthen</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Albelda</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Polarization of Tumor-Associated Neutrophil (TAN) Phenotype by TGF-β: “N1” versus “N2” TAN</article-title>
<source>Cancer Cell</source>
<year>2009</year>
<volume>16</volume>
<fpage>183</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1016/j.ccr.2009.06.017</pub-id>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Futosi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fodor</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mócsai</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Neutrophil cell surface receptors and their intracellular signal transduction pathways</article-title>
<source>Int Immunopharmacol</source>
<year>2013</year>
<volume>17</volume>
<fpage>638</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2013.06.034</pub-id>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gamrekelashvili</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kapanadze</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sablotny</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ratiu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dastagir</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lochner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karbach</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sitnow</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fleig</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sparwasser</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Notch and TLR signaling coordinate monocyte cell fate and inflammation</article-title>
<source>Elife</source>
<year>2020</year>
<volume>9</volume>
<elocation-id>e57007</elocation-id>
<pub-id pub-id-type="doi">10.7554/eLife.57007</pub-id>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gautier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cope</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bolstad</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>affy--analysis of Affymetrix GeneChip data at the probe level</article-title>
<source>Bioinformatics</source>
<year>2004</year>
<volume>20</volume>
<fpage>307</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btg405</pub-id>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="web">
<source>GEO database</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gds/">https://www.ncbi.nlm.nih.gov/gds/</ext-link>, n.d</comment>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Stat3 Phosphorylation Mediates Resistance of Primary Human T Cells to Regulatory T Cell Suppression</article-title>
<source>J Immunol</source>
<year>2011</year>
<volume>186</volume>
<fpage>3336</fpage>
<lpage>3345</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1001455</pub-id>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gubbels Bupp</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Jorgensen</surname>
<given-names>TN</given-names>
</name>
</person-group>
<article-title>Androgen-Induced Immunosuppression</article-title>
<source>Front Immunol</source>
<year>2018</year>
<volume>9</volume>
<fpage>794</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.00794</pub-id>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Levings</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>The Role of the PI3K Signaling Pathway in CD4+ T Cell Differentiation and Function</article-title>
<source>Front Immunol</source>
<year>2012</year>
<volume>3</volume>
<pub-id pub-id-type="doi">10.3389/fimmu.2012.00245</pub-id>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janghorban</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XH-F</given-names>
</name>
</person-group>
<article-title>Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target?</article-title>
<source>Front Immunol</source>
<year>2018</year>
<volume>9</volume>
<elocation-id>1649</elocation-id>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.01649</pub-id>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanduri</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Larjo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mannerström</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ullah</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Lund</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lähdesmäki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lahesmaa</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Identification of global regulators of T-helper cell lineage specification</article-title>
<source>Genome Med</source>
<year>2015</year>
<volume>7</volume>
<fpage>122</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-015-0237-0</pub-id>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>IL-6: regulator of Treg/Th17 balance</article-title>
<source>Eur J Immunol</source>
<year>2010</year>
<volume>40</volume>
<fpage>1830</fpage>
<lpage>1835</lpage>
<pub-id pub-id-type="doi">10.1002/eji.201040391</pub-id>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotz</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Miller-Graziano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>W-J</given-names>
</name>
<name>
<surname>Russom</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Moldawer</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>De</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bankey</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Petritis</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Camp</surname>
<given-names>DG</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical microfluidics for neutrophil genomics and proteomics</article-title>
<source>Nat Med</source>
<year>2010</year>
<volume>16</volume>
<fpage>1042</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2205</pub-id>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovats</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Estrogen receptors regulate innate immune cells and signaling pathways</article-title>
<source>Cell Immunol</source>
<year>2015</year>
<volume>294</volume>
<fpage>63</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellimm.2015.01.018</pub-id>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>J-J</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>K-P</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>K-H</given-names>
</name>
<name>
<surname>Altuwaijri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice</article-title>
<source>Am J Pathol</source>
<year>2012</year>
<volume>181</volume>
<fpage>1504</fpage>
<lpage>1512</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2012.07.008</pub-id>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>T Cell-Produced Transforming Growth Factor-β1 Controls T Cell Tolerance and Regulates Th1- and Th17-Cell Differentiation</article-title>
<source>Immunity</source>
<year>2007</year>
<volume>26</volume>
<fpage>579</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2007.03.014</pub-id>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Nelin</surname>
<given-names>LD</given-names>
</name>
</person-group>
<article-title>MAPK phosphatases--regulating the immune response</article-title>
<source>Nat Rev Immunol</source>
<year>2007</year>
<volume>7</volume>
<fpage>202</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1038/nri2035</pub-id>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowe</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Menendez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bushel</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Shatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kirk</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Troester</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Garantziotis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fessler</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>p53 and NF-κB coregulate proinflammatory gene responses in human macrophages</article-title>
<source>Cancer Res</source>
<year>2014</year>
<volume>74</volume>
<fpage>2182</fpage>
<lpage>2192</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1070</pub-id>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways</article-title>
<source>Cold Spring Harb Perspect Biol</source>
<year>2017</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.1101/cshperspect.a022137</pub-id>
</element-citation>
</ref>
<ref id="R35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hamaguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishioka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wing</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Adeegbe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Katayama</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sakaguchi</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals</article-title>
<source>Science</source>
<year>2014</year>
<volume>346</volume>
<fpage>1536</fpage>
<lpage>1540</lpage>
<pub-id pub-id-type="doi">10.1126/science.aaa1292</pub-id>
</element-citation>
</ref>
<ref id="R36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulder</surname>
<given-names>WJM</given-names>
</name>
<name>
<surname>Ochando</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Joosten</surname>
<given-names>LAB</given-names>
</name>
<name>
<surname>Fayad</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Therapeutic targeting of trained immunity</article-title>
<source>Nat Rev Drug Discov</source>
<year>2019</year>
<volume>18</volume>
<fpage>553</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="doi">10.1038/s41573-019-0025-4</pub-id>
</element-citation>
</ref>
<ref id="R37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Netea</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Domínguez-Andrés</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barreiro</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Chavakis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Divangahi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Joosten</surname>
<given-names>LAB</given-names>
</name>
<name>
<surname>van der Meer</surname>
<given-names>JWM</given-names>
</name>
<name>
<surname>Mhlanga</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Mulder</surname>
<given-names>WJM</given-names>
</name>
<name>
<surname>Riksen</surname>
<given-names>NP</given-names>
</name>
<etal/>
</person-group>
<article-title>Defining trained immunity and its role in health and disease</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>375</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id>
</element-citation>
</ref>
<ref id="R38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newton</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dixit</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>Signaling in innate immunity and inflammation</article-title>
<source>Cold Spring Harb Perspect Biol</source>
<year>2012</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.1101/cshperspect.a006049</pub-id>
</element-citation>
</ref>
<ref id="R39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>NF-κB: Roles and Regulation In Different CD4+ T cell subsets</article-title>
<source>Immunol Rev</source>
<year>2013</year>
<volume>252</volume>
<fpage>41</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1111/imr.12033</pub-id>
</element-citation>
</ref>
<ref id="R40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Halling</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gentleman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Parman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Halling</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gentleman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>AffyQCReport: QC report generation for affyBatch objects</article-title>
<source>R package version 1.58.0</source>
<year>2018</year>
<comment>n.d</comment>
</element-citation>
</ref>
<ref id="R41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perchet</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Petit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Banchi</surname>
<given-names>E-G</given-names>
</name>
<name>
<surname>Meunier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cumano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Golub</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>The Notch Signaling Pathway Is Balancing Type 1 Innate Lymphoid Cell Immune Functions</article-title>
<source>Front Immunol</source>
<year>2018</year>
<volume>9</volume>
<elocation-id>1252</elocation-id>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.01252</pub-id>
</element-citation>
</ref>
<ref id="R42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Platanias</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>Mechanisms of type-I- and type-II-interferon-mediated signalling</article-title>
<source>Nat Rev Immunol</source>
<year>2005</year>
<volume>5</volume>
<fpage>375</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="doi">10.1038/nri1604</pub-id>
</element-citation>
</ref>
<ref id="R43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reyes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Filbin</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Bhattacharyya</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Billman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eisenhaure</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Baron</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Blainey</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Hacohen</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>An immune-cell signature of bacterial sepsis</article-title>
<source>Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>333</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-020-0752-4</pub-id>
</element-citation>
</ref>
<ref id="R44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Huizinga</surname>
<given-names>TWJ</given-names>
</name>
</person-group>
<article-title>Rheumatoid arthritis</article-title>
<source>Lancet</source>
<year>2010</year>
<volume>376</volume>
<fpage>1094</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(10)60826-4</pub-id>
</element-citation>
</ref>
<ref id="R45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shuai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Regulation of JAK–STAT signalling in the immune system</article-title>
<source>Nat Rev Immunol</source>
<year>2003</year>
<volume>3</volume>
<fpage>900</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1038/nri1226</pub-id>
</element-citation>
</ref>
<ref id="R46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smiljanovic</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grün</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Biesen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schulte-Wrede</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Baumgrass</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stuhlmüller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maslinski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hiepe</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Burmester</surname>
<given-names>G-R</given-names>
</name>
<name>
<surname>Radbruch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Häupl</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines</article-title>
<source>J Mol Med (Berl)</source>
<year>2012</year>
<volume>90</volume>
<fpage>1295</fpage>
<lpage>1309</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-012-0907-y</pub-id>
</element-citation>
</ref>
<ref id="R47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stegmann</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Björkström</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Veber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ciesek</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Riese</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wiegand</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hadem</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suneetha</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Jaroszewicz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schlaphoff</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>
<article-title>Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection</article-title>
<source>Gastroenterology</source>
<year>2010</year>
<volume>138</volume>
<fpage>1885</fpage>
<lpage>1897</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2010.01.051</pub-id>
</element-citation>
</ref>
<ref id="R48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stolpe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van de Holtzer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van Ooijen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>de Inda</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types</article-title>
<source>Sci Rep</source>
<year>2019</year>
<volume>9</volume>
<fpage>1603</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-38179-x</pub-id>
</element-citation>
</ref>
<ref id="R49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tasaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kassai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takeshita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murota</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Okuzono</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takiguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kurisu</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission</article-title>
<source>Nat Commun</source>
<year>2018</year>
<volume>9</volume>
<fpage>2755</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-05044-4</pub-id>
</element-citation>
</ref>
<ref id="R50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kemper</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maumy-Bertrand</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pocheville</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Gribben</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Bahram</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2013</year>
<volume>110</volume>
<fpage>459</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1211130110</pub-id>
</element-citation>
</ref>
<ref id="R51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Holtzer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van Ooijen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>de Inda</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types</article-title>
<source>Scientific Reports</source>
<year>2019</year>
<volume>9</volume>
<fpage>1603</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-38179-x</pub-id>
</element-citation>
</ref>
<ref id="R52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Blay</surname>
<given-names>J-Y</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Pauwels</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pegram</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prenen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>De Ruysscher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Saba</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Slovin</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Willard-Gallo</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies</article-title>
<source>Front Genet</source>
<year>2021</year>
<volume>11</volume>
<pub-id pub-id-type="doi">10.3389/fgene.2020.598118</pub-id>
</element-citation>
</ref>
<ref id="R53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Ooijen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hornsveld</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dam-de Veen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Velter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Burgering</surname>
<given-names>B</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model</article-title>
<source>Am J Pathol</source>
<year>2018</year>
<volume>188</volume>
<fpage>1956</fpage>
<lpage>1972</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2018.05.020</pub-id>
</element-citation>
</ref>
<ref id="R54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
<name>
<surname>van Ooijen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Inda</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hatzis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Versteeg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Foekens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van de Wiel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways</article-title>
<source>Cancer Res</source>
<year>2014</year>
<volume>74</volume>
<fpage>2936</fpage>
<lpage>2945</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2515</pub-id>
</element-citation>
</ref>
<ref id="R55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walter</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Fleskens</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Frederiksen</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Rajasekhar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gerwien</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Taams</surname>
<given-names>LS</given-names>
</name>
</person-group>
<article-title>Phenotypic, Functional, and Gene Expression Profiling of Peripheral CD45RA+ and CD45RO+ CD4+CD25+CD127(low) Treg Cells in Patients With Chronic Rheumatoid Arthritis</article-title>
<source>Arthritis Rheumatol</source>
<year>2016</year>
<volume>68</volume>
<fpage>103</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1002/art.39408</pub-id>
</element-citation>
</ref>
<ref id="R56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wesseling-Rozendaal</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Holtzer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Verhaegh</surname>
<given-names>W</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Measurement of activity of developmental signal transduction pathways to quantify stem cell pluripotency and phenotypically characterize differentiated cells</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.04.14.439771</elocation-id>
<pub-id pub-id-type="doi">10.1101/2021.04.14.439771</pub-id>
</element-citation>
</ref>
<ref id="R57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wesseling-Rozendaal</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>van Doorn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Willard-Gallo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Characterization of immunoactive and immunotolerant CD4+ T cells in breast cancer by measuring activity of signaling pathways that determine immune cell function (preprint)</article-title>
<source>Cancer Biology</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.10.08.292557</pub-id>
</element-citation>
</ref>
<ref id="R58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Cancer immunotherapy: harnessing the immune system to battle cancer</article-title>
<source>J Clin Invest</source>
<year>2015</year>
<volume>125</volume>
<fpage>3335</fpage>
<lpage>3337</lpage>
<pub-id pub-id-type="doi">10.1172/JCI83871</pub-id>
</element-citation>
</ref>
<ref id="R59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaslavsky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hershberg</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Seto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Marquez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duke</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Wetmur</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Tenoever</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Sealfon</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Kleinstein</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Antiviral response dictated by choreographed cascade of transcription factors</article-title>
<source>J Immunol</source>
<year>2010</year>
<volume>184</volume>
<fpage>2908</fpage>
<lpage>2917</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0903453</pub-id>
</element-citation>
</ref>
<ref id="R60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lenardo</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Baltimore</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology</article-title>
<source>Cell</source>
<year>2017</year>
<volume>168</volume>
<fpage>37</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.12.012</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>A. Summary of the immune cell types that play a role in the innate and adaptive immune response and are characterized in this study. Dashed line around cell type indicates antigen-presenting cell type.</p>
<p>B. Simplified representation of an immune cell with relevant signal transduction pathways, illustrative ligand (oval), receptor (circle), and transcription factor (blue rectangle). Every immune cell type may have its own set of activatable signal transduction pathways.</p>
</caption>
<graphic xlink:href="EMS136379-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>A. GSE72642 (<xref ref-type="bibr" rid="R16">Du et al., 2006</xref>). Signal transduction pathway activity for different naïve immune cell types isolated from blood of 3 healthy donors.</p>
<p>B. GSE65010 (<xref ref-type="bibr" rid="R55">Walter et al., 2016</xref>). Naïve and memory CD4+ Treg and T effector cells isolated from blood samples of healthy volunteers.</p>
<p>C. GSE28490 (<xref ref-type="bibr" rid="R1">Allantaz et al., 2012</xref>). Myeloid (mDC) and plasmacytoid (pDC) subsets of dendritic cells isolated from 5 pooled blood samples, each 5 healthy volunteers.</p>
<p>Top: PAS for the respective signal transduction pathways per individual analyzed sample. First column contains individual sample annotation; top of column contains name of signaling pathway; FOXO transcription factor activity is the inverse of PI3K pathway activity. Signaling pathway activity scores are presented on log2 odds scale; color coding ranging from blue (most inactive) to red (most active). For cell isolation protocols see dataset-associated publication.</p>
<p>Bottom: Statistical comparisons between sample groups designated by numbers: exact p-values and the delta in PAS are provided. P&lt;0.01, green; p&lt;0.5, orange.</p>
</caption>
<graphic xlink:href="EMS136379-f002"/>
<graphic xlink:href="EMS136379-f003"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Immune cell types from the innate immune system, effect of immune cell activation.</title>
<p>A. GSE15743 (<xref ref-type="bibr" rid="R47">Stegmann et al., 2010</xref>). Human NK cells, resting and activated by treatment with IFNα for 6 hrs.</p>
<p>B. GSE22103 (<xref ref-type="bibr" rid="R28">Kotz et al., 2010</xref>); Neutrophils, resting and activated in vitro in whole blood with Escherichia coli lipopolysaccharide (LPS), with granulocyte-macrophage colony-simulating factor (GM-CSF) and interferon-gamma (INF-g) (GM+I) (in a microfluidic cassette). Sample data from this dataset did not pass our (rigorous) QC criteria.</p>
<p>C. GSE38351 (<xref ref-type="bibr" rid="R46">Smiljanovic et al., 2012</xref>). Monocytes of healthy volunteers, in vitro activated with TNFα, IFNα2a or IFNγ for 1.5 hour. JAK-STAT1/2 PAS have been reported before, Bouwman et al, doi: 10.3389/fimmu.2020.575074.</p>
<p>D. GSE38351 (<xref ref-type="bibr" rid="R46">Smiljanovic et al., 2012</xref>). JAK-STAT1/2 and JAK-STAT3 pathway activity in monocytes illustrating that IFN type I and type II strongly activate the activate JAK-STAT1/2 pathway in contrast to TNFα; both TNFα and interferons activate the JAK-STAT3 pathway to the same extent. The line inside the rectangle indicates the median of data.The rectangle shows the interquartile range (IQR). Its lower edge is placed at the 25% percentile (1st quartile). The upper edge is at the 75% percentile (3rd quartile). The T-shaped lines are the whiskers. Normally the range of the whiskers shows values which are between the 1st quartile (Q1) and a number (Q1 — IQR1.5). The upper whisker ends at the value = Q3 + IQR1.5. JAK-STAT1/2 PAS have been reported before, Bouwman et al, doi: 10.3389/fimmu.2020.575074.</p>
<p>E. GSE43596 (<xref ref-type="bibr" rid="R33">Lowe et al., 2014</xref>). Macrophages, from two donors (154 and 155) measured in triplicate, resting (no treatment and DMSO vehicle) and in vitro activated with LPS.</p>
</caption>
<graphic xlink:href="EMS136379-f004"/>
<graphic xlink:href="EMS136379-f005"/>
<graphic xlink:href="EMS136379-f006"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>Immune cell types from the adaptive immune system, effect of immune activation.</title>
<p>A. GSE71566, CD4+ T cells derived from cord blood of 3 donors, resting or activated using anti CD3/CD28 (A), or stimulated with IL-12 and IL-4 for differentiation towards respectively T-helper-1 (Th1) and T-helper-2 (Th2) T cell phenotype. (partly reproduced from: Wesseling et al, <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.10.08.292557v1">https://www.biorxiv.org/content/10.1101/2020.10.08.292557v1</ext-link>, currently under review Frontiers Immunology)</p>
<p>B. GSE63129; CD8+ T cells, activated by specific antigen, and immune-suppressed by presence of Treg cells. Antigen-specific (Tet+) and non-specific (Tet-) CD8+ T cells with Treg cells (Treg+) or without Treg (Treg-) (<xref ref-type="bibr" rid="R35">Maeda et al., 2014</xref>).</p>
<p>C. GSE39411; B cells from healthy donors, resting and activated with anti-IgM for 210 min (<xref ref-type="bibr" rid="R50">Vallat et al., 2013</xref>).</p>
</caption>
<graphic xlink:href="EMS136379-f007"/>
<graphic xlink:href="EMS136379-f008"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>Dendritic cells, effect of immune activation.</title>
<p>GSE18791(<xref ref-type="bibr" rid="R59">Zaslavsky et al., 2010</xref>). Dendritic cells (Monocyte-derived DCs) from two donors, resting and activated by infection with Newcastle disease virus (NDV), at 1, 2, 4, 6, 8, 10, 12, 14, 16 and 18 hours after infection versus control.</p>
</caption>
<graphic xlink:href="EMS136379-f009"/>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<title>Clinical studies, patients with rheumatoid arthritis (RA)</title>
<p>A. GSE93272 (<xref ref-type="bibr" rid="R49">Tasaki et al., 2018</xref>), whole blood samples from healthy volunteers and RA patients without prior treatment. JAK-STAT1/2, JAK-STAT3 and TGFβ PAS in log2 odds. F: female, M: Male</p>
<p>B. GSE65010(<xref ref-type="bibr" rid="R55">Walter et al., 2016</xref>), CD4+ naïve and memory Treg and T effector cells of RA patients. HC: healthy control, RA: rheumatoid arthritis and Teffs: T effector cells.</p>
<p>Boxplots were made using R. Exact p-values are indicated on top of the boxplots. The boxplot shows minimum, maximum, median, first quartile, third quartile and outliers which are plotted as individual points outside the minimum and maximum.</p>
</caption>
<graphic xlink:href="EMS136379-f010"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<p>A. I-PAP for myeloid and lymphoid lineage, and I-PAP for cell types within a lineage. I-PAP <bold>lineage</bold>: STPs that are differentially active in lymphoid versus myeloid lineage; I-PAP <bold>cell type specific</bold>: STPs that are differentially active in the indicated cell type within a lineage (in addition to the lineage I-PAP).</p>
<p>B. I-PAP for CD4+ naïve versus memory T effector and Treg cells combined (Treg/Teffector), and I-PAP for Treg naïve versus Treg memory (Treg specific) and Teffector naïve versus Teffector memory (Treg specific). I-PAP <bold>naïve:</bold> STPs that are more active in both naïve Treg and Teffector cells (Treg/Teffector); or more active in naïve Treg cells specifically (Treg specific) or naïve Teffector cells specifically (Teffector specific); I-PAP <bold>memory:</bold> STPs that are more active in both memory Treg and Teffector cells (Treg/Teffector); or more active in memory Treg cells specifically (Treg specific) or memory Teffector cells specifically (Teffector specific).</p>
<p>C. I-PAP for myeloid (mDC) and plasmacytoid (pDC) dendritic cells. I-PAP: STPs that are differentially active in mDCs versus pDCs.</p>
<p>The pathway that is listed is significantly more active (p&lt;0.01), see <xref ref-type="fig" rid="F2">Figure 2</xref>. * Second independent dataset analyzed, see <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>.</p>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">
<italic>Lineage</italic>
</th>
<th valign="top" align="left">I-PAP <italic>lineage</italic>
</th>
<th valign="top" align="left">
<italic>Cell type</italic>
</th>
<th valign="top" align="left">I-PAP <italic>cell type specific</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Myeloid lineage</td>
<td valign="top" align="left">MAPK-AP1</td>
<td valign="top" align="left">Monocytes*</td>
<td valign="top" align="left">PI3K<break/>AR</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">MAPK-AP1</td>
<td valign="top" align="left">Polymorphonuclear<break/>Neutrophils</td>
<td valign="top" align="left">NFκB<break/>JAK-STAT3<break/>TGFβ</td>
</tr>
<tr>
<td valign="top" align="left">Lymphoid</td>
<td valign="top" align="left">PI3K</td>
<td valign="top" align="left">NK cells*</td>
<td valign="top" align="left">TGFβ</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">PI3K</td>
<td valign="top" align="left">B cells*</td>
<td valign="top" align="left">JAK-STAT1/2</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">PI3K</td>
<td valign="top" align="left">CD4+ T cells*</td>
<td valign="top" align="left">JAK-STAT3<break/>Notch</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">PI3K</td>
<td valign="top" align="left">CD8+ T cells</td>
<td valign="top" align="left">NFκB</td>
</tr>
<tr>
<td valign="top" align="left" colspan="4" style="border-bottom: hidden; border-right: hidden; border-left: hidden">A</td>
</tr>
</tbody>
</table>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">
<italic>CD4+ T cell type</italic>
</th>
<th valign="top" align="left">I-PAP <italic>naïve</italic>
</th>
<th valign="top" align="left">I-PAP <italic>memory</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Treg/T effector</td>
<td valign="top" align="left">PI3K</td>
<td valign="top" align="left">MAPK<break/>NFκB<break/>JAK-STAT1/2<break/>JAK-STAT3<break/>TGFβ</td>
</tr>
<tr>
<td valign="top" align="left">Treg, specific</td>
<td valign="top" align="left"/>
<td valign="top" align="left">NFκB<break/>TGFβ</td>
</tr>
<tr>
<td valign="top" align="left">T effector, specific</td>
<td valign="top" align="left"/>
<td valign="top" align="left">AR<break/>ER<break/>MAPK<break/>TGFβ</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3" style="border-bottom: hidden; border-right: hidden; border-left: hidden">B</td>
</tr>
</tbody>
</table>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">
<italic>DC cell type</italic>
</th>
<th valign="top" align="left">I-PAP</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">pDC</td>
<td valign="top" align="left">AR<break/>JAK-STAT1/2</td>
</tr>
<tr>
<td valign="top" align="left">mDC</td>
<td valign="top" align="left">ER<break/>NFκB<break/>JAK-STAT3<break/>Notch</td>
</tr>
<tr>
<td valign="top" align="left" colspan="2" style="border-bottom: hidden; border-right: hidden; border-left: hidden">C</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float" orientation="portrait">
<label>Table 2</label>
<caption>
<title>I-PAP of in vitro cytokine-activated immune cells of the innate immune system and dendritic cells, compared to their resting immune counterpart.</title>
<p>I-PAP <bold>resting</bold>: STPs that are more active in functionally resting/naïve cells; I-PAP <bold>activated</bold>: STPs that are more active in functionally activated cells. Shared activated pathways: STPs that are activated by multiple used stimuli; Specific activated pathways: STPs that are specifically activated by the stimulus (in addition to shared activated STPs). The pathway that is listed is significantly more active (p&lt;0.01), see <xref ref-type="fig" rid="F3">Figure 3</xref> and <xref ref-type="fig" rid="F5">5</xref>.</p>
<p>NDV: Newcastle Disease Virus. * other independent dataset(s) analyzed, see <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>
</p>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">Cell type, <italic>activator used</italic>
</th>
<th valign="top" align="left">I-PAP resting</th>
<th valign="top" align="left">I-PAP activated cells</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Neutrophils,<break/>
<italic>activated by LPS, GM-CSF, IFN (shared activated pathways)</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">PI3K<break/>NFκB<break/>JAK-STAT1/2<break/>JAK-STAT3<break/>TGFβ</td>
</tr>
<tr>
<td valign="top" align="left">Neutrophils,<break/>
<italic>LPS, specific activated pathways</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">MAPK</td>
</tr>
<tr>
<td valign="top" align="left">Monocytes*,<break/>
<italic>activated by TNFα, IFNα, or IFNγ (shared activated pathways)</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">JAK-STAT3<break/>TGFβ<break/>JAK-STAT1/2</td>
</tr>
<tr>
<td valign="top" align="left">Monocytes,<break/>
<italic>TNFα, specific activated pathways</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">PI3K<break/>NFκB</td>
</tr>
<tr>
<td valign="top" align="left">Monocytes,<break/>
<italic>Interferon, specific activated pathways</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">AR<break/>MAPK<break/>JAK-STAT1/2<break/>Notch</td>
</tr>
<tr>
<td valign="top" align="left">Macrophages*,<break/>
<italic>activated by LPS</italic>
</td>
<td valign="top" align="left">PI3K<break/>MAPK</td>
<td valign="top" align="left">NFκB<break/>JAK-STAT1/2<break/>JAK-STAT3<break/>TGFβ<break/>Notch</td>
</tr>
<tr>
<td valign="top" align="left">Dendritic cells*,<break/>
<italic>activated by infection with NDV (virus)</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">NFκB<break/>JAK-STAT1/2<break/>TGFβ</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T3" position="float" orientation="portrait">
<label>Table 3</label>
<caption>
<p>I-PAP of in vitro cytokine-activated immune cells of the adaptive immune system, compared to their resting counterpart. I-PAP <bold>resting</bold>: STPs that are more active in functionally resting/naïve cells; I-PAP <bold>activated</bold>: STPs that are more active in functionally activated cells. The pathway that is listed is significantly more active (p&lt;0.01), see <xref ref-type="fig" rid="F4">figure 4</xref>. * other independent dataset analyzed, see <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>
</p>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">Cell type,<break/>
<italic>activator used</italic>
</th>
<th valign="top" align="left">I-PAP<break/>Resting</th>
<th valign="top" align="left">I-PAP<break/>Activated</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">CD4+ T cell*,<break/>
<italic>anti-CD3/CD28</italic>
</td>
<td valign="top" align="left">TGFβ</td>
<td valign="top" align="left">PI3K<break/>NFκB<break/>JAK-STAT1/2<break/>JAK-STAT3<break/>Notch</td>
</tr>
<tr>
<td valign="top" align="left">B cells,<break/>
<italic>anti-IgM</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">JAK-STAT1/2<break/>JAK-STAT3<break/>Notch</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T4" position="float" orientation="portrait">
<label>Table 4</label>
<caption>
<p>I-PAP of CD4+ T cells differentiated to Th phenotype. I-PAP <bold>activated CD4+ Tcell</bold>: STPs that are more active in activated CD4+ T cells compared to their differentiated counterpart. I-PAP <bold>Differentiated to Th cell type</bold> STPs that are more active Th cell phenotypes compared to activated CD4+ T cells. The pathway that is listed is significantly more active (p&lt;0.01). * other independent dataset analyzed, see <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>
</p>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">CD4+ T cell subtype,<break/>
<italic>cytokine used to differentiate to subtype</italic>
</th>
<th valign="top" align="left">I-PAP<break/>activated CD4+ T cell</th>
<th valign="top" align="left">I-PAP<break/>Differentiated to Th cell type</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Th1*,<break/>
<italic>IL-12</italic>
</td>
<td valign="top" align="left"/>
<td valign="top" align="left">NFκB<break/>TGF-β</td>
</tr>
<tr>
<td valign="top" align="left">Th2*,<break/>
<italic>IL-4</italic>
</td>
<td valign="top" align="left">PI3K<break/>NFκB<break/>JAK-STAT1/2</td>
<td valign="top" align="left"/>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
